Exome Asset Management LLC Acquires Shares of 263,841 Immunome, Inc. $IMNM

Key Points

• Exome Asset Management LLC invested approximately $1.78 million in Immunome, acquiring 263,841 shares, giving it a 0.30% ownership stake as of the latest reporting period.
• Several institutional investors, including T. Rowe Price and Vanguard Group, significantly increased their stakes in Immunome during the first quarter, reflecting growing confidence in the company's potential.
• Immunome has received multiple "outperform" and "buy" ratings from analysts, with target prices ranging from $18.00 to $26.00, suggesting a positive outlook for the stock despite its recent price decline.

Exome Asset Management LLC acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 263,841 shares of the company's stock, valued at approximately $1,776,000. Exome Asset Management LLC owned about 0.30% of Immunome at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IMNM. BNP Paribas Financial Markets purchased a new stake in shares of Immunome during the 4th quarter worth $70,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Immunome during the 1st quarter worth $95,000. KLP Kapitalforvaltning AS lifted its position in shares of Immunome by 140.8% during the 1st quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock worth $115,000 after purchasing an additional 10,000 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of Immunome by 49.0% during the 1st quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company's stock worth $117,000 after purchasing an additional 5,712 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Immunome by 66.2% during the 1st quarter. Arizona State Retirement System now owns 18,764 shares of the company's stock worth $126,000 after purchasing an additional 7,476 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Stock Performance

NASDAQ IMNM traded down $0.47 during trading on Friday, reaching $9.21. The company's stock had a trading volume of 5,211,887 shares, compared to its average volume of 999,354. The firm has a market cap of $801.64 million, a price-to-earnings ratio of -2.99 and a beta of 1.92. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $16.73. The business's fifty day moving average price is $9.94 and its 200-day moving average price is $8.83.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. The company had revenue of $4.02 million for the quarter, compared to analyst estimates of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. As a group, sell-side analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IMNM has been the subject of several recent analyst reports. Guggenheim reaffirmed a "buy" rating and set a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. JPMorgan Chase & Co. reduced their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Craig Hallum initiated coverage on shares of Immunome in a research report on Friday, September 5th. They issued a "buy" rating and a $26.00 price target for the company. Finally, Wedbush reissued an "outperform" rating and issued a $21.00 price target on shares of Immunome in a research report on Thursday, August 7th. Nine analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $22.89.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.